Novo Nordisk Pharmatech invests $200 million in new production facility

Danish diabetes and obesity giant Novo Nordisk (NOV: N) says its Novo Nordisk Pharmatech unit is building a new factor to meet significantly higher demand for raw materials, following its purchase in March of a site in Køge.

Novo Nordisk Pharmatech is now investing 1.5 billion Danish kroner ($200.9 million) in around 8,000 m² facility containing production, storage, office, and laboratory on this site. The facility is expected to be ready for production in 2027. The new plant, located at Ådalen 16, will primarily supply raw materials for Novo Nordisk’s production of medicine to fight critical chronic diseases. It is expected that the new factory will create around 50 new jobs.

“This is the largest investment in Novo Nordisk Pharmatech’s 75-year history. We are in a period of growth. In accordance with our growth strategy, we are expanding our production to ensure an even more robust and reliable delivery of our products. The location in Køge is ideal, as we can draw on the extensive know-how we have at our current factory – and furthermore, the infrastructure is optimal, with Køge Nord station so close to our new site,” says Ulla Grove Krogsgaard Thomsen, chief executive of Novo Nordisk Pharmatech A/S.